Sarah Bennett
The AstraZeneca vaccine was one of the first to be approved for use in the UK, and it was used a lot more widely than in other European countries. However, the vaccine was found to be less effective against the South African variant, with only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 variant. This has caused concern as the South African variants share similar mutations to other variants, leaving those vaccinated with the AstraZeneca vaccine potentially exposed. Despite this, there is good evidence that the AstraZeneca vaccine offers a high level of protection against severe disease, and it is believed to give protection against the UK variant.
| Characteristics | Values |
|---|---|
| Does the AstraZeneca vaccine protect against the UK variant? | It is believed to give protection against the UK variant, but less so against the South African variant. |
| Protection against the South African variant | A study found that two doses of the AstraZeneca vaccine had only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant. |
| T-cell protection | The AstraZeneca vaccine may provide more durable T-cell protection, but there is not enough evidence to support this claim. |
| Hospitalization rates | The UK, which relied heavily on the AstraZeneca vaccine, has a more stable hospitalization rate than other parts of Europe. |
| Comparison with other vaccines | The AstraZeneca vaccine may provide longer-lasting protection than mRNA vaccines like Pfizer's. |
Explore related products
What You'll Learn
- AstraZeneca vaccine may provide longer-lasting protection than mRNA vaccines
- AstraZeneca vaccine is less effective against the South African variant
- The UK variant is believed to give protection against the UK variant
- AstraZeneca vaccine may reduce the number of infections
- AstraZeneca vaccine may provide protection against the risk of hospitalisation and death
AstraZeneca vaccine may provide longer-lasting protection than mRNA vaccines
The AstraZeneca vaccine is believed to offer protection against the UK variant of COVID-19, but is less effective against the South African strain. While the vaccine has been shown to be only 10.4% effective against the B.1.351 South African variant, it is important to note that there were no hospitalizations or deaths observed in the study.
In comparison to mRNA vaccines, such as those developed by Pfizer and Moderna, the AstraZeneca vaccine may provide longer-lasting protection, especially in older individuals. This is based on the observation that the UK, which relied more heavily on the AstraZeneca vaccine, has experienced more stable hospitalization rates compared to continental Europe, where other vaccines were used more frequently.
The theory behind this potential advantage is that the AstraZeneca vaccine may offer more durable "T cell protection". T cells are a critical component of our immune system, distinct from antibodies. While mRNA vaccines elicit a stronger initial antibody response, this protection diminishes relatively quickly, within 4-6 months. In contrast, the AstraZeneca vaccine, a viral vector vaccine, may produce a longer-lasting T cell response that contributes to more durable immune memory. This could slow the decline of antibodies and enhance the T cell response.
The stability of the vaccine components may also play a role. The RNA in mRNA vaccines is fragile and does not persist long in the body, typically lasting only about a week. On the other hand, the DNA delivered by the AstraZeneca vaccine's adenovirus vector is more stable and is expected to remain in the body for a longer duration, potentially enabling a more prolonged activation of the immune system and resulting in longer-lasting protection.
However, it is important to note that these theories are speculative at this stage, as direct tests specifically examining the duration of protection have not yet been conducted. While the CEO of AstraZeneca has suggested this potential advantage, there is not yet sufficient evidence to support the claim. Nonetheless, the longer history of adenovirus vector vaccines, compared to the newer mRNA vaccines, provides a level of confidence in their effectiveness and durability.
Vaccine Efficacy: Delta Variant and Immunization
You may want to see also
Explore related products
AstraZeneca vaccine is less effective against the South African variant
The AstraZeneca vaccine is believed to offer protection against the UK variant. However, the vaccine is less effective against the South African variant.
A study published in the New England Journal of Medicine found that two doses of the AstraZeneca vaccine were only 10.4% effective against mild-to-moderate infections caused by the B.1.351 South Africa variant. This has caused concern as the South African variant shares similar mutations with other variants, potentially exposing vaccinated individuals to multiple variants.
The reduced efficacy of the AstraZeneca vaccine against the South African variant is attributed to the specific mutations in the spike protein of the virus. These mutations, particularly K417N, E484K, and N501Y, are located in the receptor-binding domain, which is the part of the spike protein that attaches to human cells.
While the AstraZeneca vaccine may not provide strong protection against mild disease caused by the South African variant, it is important to note that it may still offer protection against severe disease and hospitalization. The company has stated that the neutralizing antibody activity of their vaccine is equivalent to that of other COVID-19 vaccines that have demonstrated protection against severe disease. Additionally, initial data indicates that other immune responses, such as T-cell responses, may remain intact against the South African variant.
To address the reduced efficacy against the South African variant, Oxford University and AstraZeneca have started adapting their vaccine. They aim to rapidly advance the development of an updated vaccine, which could be ready for delivery by Autumn if needed. In the meantime, individuals who have the opportunity to receive the current AstraZeneca vaccine are still encouraged to do so to protect themselves against the risk of hospitalization and death.
Antibodies: What They Don't Do and Why
You may want to see also
Explore related products
The UK variant is believed to give protection against the UK variant
The Oxford-AstraZeneca vaccine is believed to give protection against the UK variant. However, it is important to note that the vaccine is less effective against the South African variant. According to a clinical trial published in the New England Journal of Medicine, two doses of the AstraZeneca vaccine had only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South African variant. This has raised concerns as the South African variants share similar mutations with other variants, potentially exposing vaccinated individuals to multiple strains.
While the AstraZeneca vaccine may not be as effective against the South African variant, it still offers protection against severe COVID-19 disease. Clinical trials provide good evidence that the AstraZeneca vaccine, along with the Pfizer/BioNTech and Moderna vaccines authorised for use in the UK, offer a high level of protection against severe illness. This is particularly true for individuals who have received a single dose and are exposed to the virus after producing an immune response, which typically occurs within approximately two weeks.
Additionally, there are indications that the AstraZeneca vaccine may reduce the number of infections. In a subsection of the AstraZeneca trial, participants who received the first dose of the vaccine experienced an estimated 49% reduction in asymptomatic infections compared to the placebo group. This suggests that the vaccine could have a substantial impact on transmission by reducing the number of infected individuals in the population.
The UK relied heavily on the AstraZeneca vaccine in its national coronavirus immunisation programme in 2021. However, due to reports of rare blood clots, many European countries restricted its use or abandoned it altogether. Despite this, the AstraZeneca vaccine has been widely distributed to poorer countries through UN-coordinated programs as it is cheaper and easier to produce and distribute.
While the AstraZeneca vaccine may offer protection against the UK variant, ongoing research and development are necessary to address emerging variants and ensure long-term protection.
Rabies Vaccinations: Are Repeat Animal Shots Needed?
You may want to see also
Explore related products
AstraZeneca vaccine may reduce the number of infections
The AstraZeneca vaccine may reduce the number of infections. Clinical trials have shown that the AstraZeneca vaccine offers a high level of protection against severe disease for individuals who have received a single dose and are exposed to the virus after producing an immune response (approximately 2 weeks). There is also good evidence that the vaccine is highly effective at protecting people against symptomatic COVID-19 disease.
In addition to protecting against severe COVID-19 disease, there are indications from clinical trials that the AstraZeneca vaccine might reduce the number of infections. For example, participants in one sub-section of the AstraZeneca trial were swabbed weekly and PCR-tested for SARS-CoV-2 after receiving the first dose of the vaccine. There was an estimated 49% reduction in asymptomatic infections in the vaccinated group compared to the placebo group. The researchers suggest that the observed reduction shows that the vaccine "may have a substantial impact on transmission by reducing the number of infected individuals in the population".
The AstraZeneca vaccine uses a genetically engineered adenoviral vector to carry the DNA for the Sars-CoV-2 spike protein into human cells. It then becomes part of the host cell and triggers an immune response in the body. This immune response is believed to be longer-lasting than that of mRNA vaccines, such as those produced by Pfizer-BioNTech and Moderna, due to the T cell-based immune response stimulated by the AstraZeneca vaccine. It is a lot harder for a virus to escape a T cell-based immune response, so a vaccine that generates strong T cell immunity should help retain effectiveness over time against variants.
However, it is important to note that the AstraZeneca vaccine has been found to be less effective against the South African variant of COVID-19. A clinical trial found that two doses of the vaccine had only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant. This has caused some countries to switch to using the pricier mRNA vaccines for booster shots, and the AstraZeneca vaccine is now rarely used globally.
Vaccination Benefits: Weighing the Evidence and Risks
You may want to see also
Explore related products
AstraZeneca vaccine may provide protection against the risk of hospitalisation and death
The AstraZeneca vaccine may offer protection against the risk of hospitalisation and death. While the vaccine has been found to be only 10.4% effective against the B.1.351 South Africa variant, no cases of hospitalisation or death were observed in a clinical trial. The UK variant is believed to be among the variants that the AstraZeneca vaccine can protect against.
The AstraZeneca vaccine uses a genetically engineered adenoviral vector to carry the DNA for the Sars-CoV-2 spike protein into human cells. This triggers an immune response in the body, producing antibodies to fight off the virus. The vaccine is administered in two doses.
While the AstraZeneca vaccine may provide protection against the UK variant, it is less effective against the South African variant. A clinical trial found that out of 750 vaccine recipients, 19 (2.5%) developed mild to moderate COVID-19 more than 14 days after the second dose, compared to 3.2% in the placebo group. This is a cause for concern as the South African variant shares similar mutations with other variants, leaving those vaccinated with the AstraZeneca vaccine potentially exposed.
However, it is important to note that the lack of severe COVID-19 cases in the trial may be due to the relatively young median age of the participants (30 years). Additionally, there is evidence that the AstraZeneca vaccine may provide longer-lasting protection than mRNA vaccines like Pfizer's. The theory is that the AstraZeneca vaccine may offer more durable "T cell protection". T cells are a crucial part of the immune system, and adenovirus vector vaccines like AstraZeneca's have been around for decades, while mRNA vaccines are relatively new.
While the AstraZeneca vaccine may provide some protection, it is important to continue practicing safety measures and to follow public health guidelines to reduce the risk of infection and transmission.
Judge Seizes Vaccine Property: Italian Scientists' Saga
You may want to see also
Frequently asked questions
It is believed that the AstraZeneca vaccine does offer protection against the UK variant, but it is less effective against the South African variant.
Clinical trials have shown that the AstraZeneca vaccine is highly effective at protecting against symptomatic COVID-19 disease. There was an estimated 49% reduction in asymptomatic infections in the vaccinated group compared to the placebo group.
There is some evidence that the AstraZeneca vaccine may provide longer-lasting protection against variants such as Delta and Omicron due to its ability to generate strong T cell immunity. However, studies have shown that the vaccine is less effective against the South African variant.
The AstraZeneca vaccine was widely used in the UK, but some European countries restricted its use or abandoned it due to rare reports of blood clots. The vaccine was also found to be less effective against certain variants, particularly the South African variant.
While the AstraZeneca vaccine may not be as effective against certain variants, it is still important to get vaccinated to protect against the risk of hospitalization and death. It is also important to remember that all vaccines, including AstraZeneca, have saved countless lives.
